Main Street Research LLC bought a new position in Astrazeneca Plc (NYSE:AZN – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund bought 371,217 shares of the company’s stock, valued at approximately $65,149,000. Astrazeneca comprises approximately 3.7% of Main Street Research LLC’s investment portfolio, making the stock its 10th biggest holding.
A number of other hedge funds have also added to or reduced their stakes in AZN. Bank of Montreal Can grew its stake in Astrazeneca by 344.6% in the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after acquiring an additional 2,695,793 shares in the last quarter. Holocene Advisors LP grew its stake in Astrazeneca by 41.8% in the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after acquiring an additional 1,807,565 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its stake in Astrazeneca by 11,190.9% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock worth $317,107,000 after acquiring an additional 1,790,874 shares in the last quarter. Raymond James Financial Inc. grew its stake in Astrazeneca by 64.8% in the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock worth $264,373,000 after acquiring an additional 1,487,662 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.
Astrazeneca Price Performance
Shares of AZN opened at $187.24 on Monday. The company has a 50 day moving average price of $191.66 and a 200-day moving average price of $183.08. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The stock has a market capitalization of $290.39 billion, a PE ratio of 28.11, a PEG ratio of 1.54 and a beta of 0.26. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.
Analyst Ratings Changes
A number of brokerages have commented on AZN. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research note on Thursday. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Thursday, May 14th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.
View Our Latest Stock Analysis on AZN
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Recommended Stories
- Five stocks we like better than Astrazeneca
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
